Addition of a TLR7 agonist to an acellular pertussis vaccine enhances Th1 and Th17 responses and protective immunity in a mouse model

Vaccine

Volumn 35, Issue 39, 2017, Pages 5256-5263

  Misiak, Alicja ^a   Leuzzi, Rosanna ^b   Allen, Aideen C ^a   Galletti, Bruno ^b   Baudner, Barbara C ^b   D'Oro, Ugo ^b   O'Hagan, Derek T ^b   Pizza, Mariagrazia ^b   Seubert, Anja ^b   Mills, Kingston H G ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b GSK   (Italy)

Author keywords

Adjuvant; Pertussis; Protective immunity; TLR7; Vaccine

Indexed keywords

IMMUNOGLOBULIN G2A ANTIBODY; PERTUSSIS VACCINE; TOLL LIKE RECEPTOR 7 AGONIST; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG; IMMUNOLOGICAL ADJUVANT; MEMBRANE PROTEIN; TLR7 PROTEIN, MOUSE; TOLL LIKE RECEPTOR 7;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIGEN SPECIFICITY; ARTICLE; CONTROLLED STUDY; DRUG POTENTIATION; FEMALE; IMMUNE RESPONSE; IMMUNOGENICITY; INFECTION PREVENTION; MOUSE; NONHUMAN; PERTUSSIS; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH17 CELL; VACCINATION; AGONISTS; ANIMAL; BAGG ALBINO MOUSE; BORDETELLA PERTUSSIS; C57BL MOUSE; CHO CELL LINE; CRICETULUS; DISEASE MODEL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMORAL IMMUNITY; IMMUNOASSAY; IMMUNOLOGY; METABOLISM; PATHOGENICITY; PHYSIOLOGY; PROCEDURES;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; BORDETELLA PERTUSSIS; CHO CELLS; CRICETULUS; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNITY, HUMORAL; IMMUNOASSAY; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PERTUSSIS VACCINE; TH1 CELLS; TH17 CELLS; TOLL-LIKE RECEPTOR 7; VACCINATION;

EID: 85027455507     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2017.08.009     Document Type: Article

References (22)

1. Klein, N.P., Bartlett, J., Rowhani-Rahbar, A., Fireman, B., Baxter, R., Waning protection after fifth dose of acellular pertussis vaccine in children. N Engl J Med 367 (2012), 1012–1019.
2. Warfel, J.M., Zimmerman, L.I., Merkel, T.J., Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model. Proc Natl Acad Sci U S A 111 (2014), 787–792.
3. Mills, K.H., Ryan, M., Ryan, E., Mahon, B.P., A murine model in which protection correlates with pertussis vaccine efficacy in children reveals complementary roles for humoral and cell-mediated immunity in protection against Bordetella pertussis. Infect Immun 66 (1998), 594–602.
4. Mahon, B.P., Brady, M.T., Mills, K.H., Protection against Bordetella pertussis in mice in the absence of detectable circulating antibody: implications for long-term immunity in children. J Infect Dis 181 (2000), 2087–2091.
5. Ross, P.J., Sutton, C.E., Higgins, S., Allen, A.C., Walsh, K., Misiak, A., Lavelle, E.C., McLoughlin, R.M., Mills, K.H., Relative contribution of Th1 and Th17 cells in adaptive immunity to Bordetella pertussis: towards the rational design of an improved acellular pertussis vaccine. PLoS Pathog, 9, 2013, e1003264.
6. Higgs, R., Higgins, S.C., Ross, P.J., Mills, K.H., Immunity to the respiratory pathogen Bordetella pertussis. Mucosal Immunol 5 (2012), 485–500.
7. Warfel, J.M., Merkel, T.J., Bordetella pertussis infection induces a mucosal IL-17 response and long-lived Th17 and Th1 immune memory cells in nonhuman primates. Mucosal Immunol 6 (2013), 787–796.
8. Mooi, F.R., van Oirschot, H., Heuvelman, K., van der Heide, H.G., Gaastra, W., Willems, R.J., Polymorphism in the Bordetella pertussis virulence factors P.69/pertactin and pertussis toxin in The Netherlands: temporal trends and evidence for vaccine-driven evolution. Infect Immun 66 (1998), 670–675.
9. Pizza, M., Covacci, A., Bartoloni, A., Perugini, M., Nencioni, L., De Magistris, M.T., Villa, L., Nucci, D., Manetti, R., Bugnoli, M., et al. Mutants of pertussis toxin suitable for vaccine development. Science 246 (1989), 497–500.
10. Greco, D., Salmaso, S., Mastrantonio, P., Giuliano, M., Tozzi, A.E., Anemona, A., Ciofi degli Atti, M.L., Giammanco, A., Panei, P., Blackwelder, W.C., Klein, D.L., Wassilak, S.G., A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group. N Engl J Med 334 (1996), 341–348.
11. Salmaso, S., Mastrantonio, P., Wassilak, S.G., Giuliano, M., Anemona, A., Giammanco, A., Tozzi, A.E., Ciofi degli Atti, M.L., Greco, D., Persistence of protection through 33 months of age provided by immunization in infancy with two three-component acellular pertussis vaccines stage II Working Group. Vaccine 16 (1998), 1270–1275.
12. Garcon, N., Van Mechelen, M., Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems. Expert Rev Vaccines 10 (2011), 471–486.
13. Donadei, A., Balocchi, C., Mancini, F., Proietti, D., Gallorini, S., O'Hagan, D.T., D'Oro, U., Berti, F., Baudner, B.C., Adamo, R., The adjuvant effect of TLR7 agonist conjugated to a meningococcal serogroup C glycoconjugate vaccine. Eur J Pharm Biopharm 107 (2016), 110–119.
14. Liu, R., Wang, J., Yang, Y., Khan, I., Zhu, N., Rabies virus lipopeptide conjugated to a TLR7 agonist improves the magnitude and quality of the Th1-biased humoral immune response in mice. Virology 497 (2016), 102–110.
15. Wu TY, Singh M, Miller AT, De Gregorio E, Doro F, D'Oro U, Skibinski DA, Mbow ML, Bufali S, Herman AE, Cortez A, Li Y, Nayak BP, Tritto E, Filippi CM, Otten GR, Brito LA, Monaci E, Li C, Aprea S, Valentini S, Calabromicron S, Laera D, Brunelli B, Caproni E, Malyala P, Panchal RG, Warren TK, Bavari S, O'Hagan DT, Cooke MP, Valiante NM. Rational design of small molecules as vaccine adjuvants. Sci Transl Med 2014;6:263ra160.
16. Agnolon, V., Bruno, C., Leuzzi, R., Galletti, B., D'Oro, U., Pizza, M., Seubert, A., O'Hagan, D.T., Baudner, B.C., The potential of adjuvants to improve immune responses against TdaP vaccines: a preclinical evaluation of MF59 and monophosphoryl lipid A. Int J Pharm 492 (2015), 169–176.
17. Misiak, A., Wilk, M.M., Raverdeau, M., Mills, K.H., IL-17-Producing innate and pathogen-specific tissue resident memory γδ T cells expand in the lungs of Bordetella pertussis-infected mice. J Immunol 198 (2017), 363–374.
18. Walsh, K.P., Mills, K.H., Dendritic cells and other innate determinants of T helper cell polarisation. Trends Immunol 34 (2013), 521–530.
19. Holland, G.P., Holland, N., Steward, M.W., Interferon-gamma potentiates antibody affinity in mice with a genetically controlled defect in affinity maturation. Clin Exp Immunol 82 (1990), 221–226.
20. Goff, P.H., Hayashi, T., Martínez-Gil, L., Corr, M., Crain, B., Yao, S., Cottam, H.B., Chan, M., Ramos, I., Eggink, D., Heshmati, M., Krammer, F., Messer, K., Pu, M., Fernandez-Sesma, A., Palese, P., Carson, D.A., Synthetic toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responses. J Virol 89 (2015), 3221–3235.
21. Zhang, W.W., Matlashewski, G., Immunization with a Toll-like receptor 7 and/or 8 agonist vaccine adjuvant increases protective immunity against Leishmania major in BALB/c mice. Infect Immun 76 (2008), 3777–3783.
22. Buonsanti, C., Balocchi, C., Harfouche, C., Corrente, F., Galli Stampino, L., Mancini, F., Tontini, M., Malyala, P., Bufali, S., Baudner, B., De Gregorio, E., Valiante, N.M., O'Hagan, D.T., Rappuoli, R., D'Oro, U., Novel adjuvant Alum-TLR7 significantly potentiates immune response to glycoconjugate vaccines. Sci Rep, 6, 2016, 29063.